Klaus Pantel

Biography
Klaus Pantel is a global pioneer in liquid biopsy whose groundbreaking research established circulating tumor cells (CTCs) and micrometastases as clinically meaningful biomarkers. His work revealed how tumor cells disseminate early in cancer progression and provided the first evidence that these rare cells could guide prognosis and therapy monitoring. Pantels leadership extended beyond the lab with the founding of the European Liquid Biopsy Society, creating the infrastructure and collaborations needed to advance blood-based cancer detection worldwide. His contributions have transformed liquid biopsy from a research concept into a cornerstone of precision oncology, enabling earlier detection, real-time treatment monitoring, and more effective cancer care.

---

Talk
Liquid Biopsy: From discovery to clinical implementation
Liquid Biopsy including circulating tumor cells, cell free DNA and extracellular vesicles have received enormous attention as new biomarkers and subject of translational research. Clinical applications in-clude early cancer detection, improved cancer staging, early detection of relapse, real-time monitor-ing of therapeutic efficacy and detection of therapeutic targets and resistance mechanisms.